JP5719779B2 - キナゾリノン化合物 - Google Patents

キナゾリノン化合物 Download PDF

Info

Publication number
JP5719779B2
JP5719779B2 JP2011542631A JP2011542631A JP5719779B2 JP 5719779 B2 JP5719779 B2 JP 5719779B2 JP 2011542631 A JP2011542631 A JP 2011542631A JP 2011542631 A JP2011542631 A JP 2011542631A JP 5719779 B2 JP5719779 B2 JP 5719779B2
Authority
JP
Japan
Prior art keywords
compound
optionally substituted
formula
acid
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011542631A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012513416A5 (enExample
JP2012513416A (ja
Inventor
ペネロペ ジェーン ハギンズ
ペネロペ ジェーン ハギンズ
ジャック ゴードン パーソンズ
ジャック ゴードン パーソンズ
マイケル マクノートン
マイケル マクノートン
Original Assignee
プラナ バイオテクノロジー リミティッド
プラナ バイオテクノロジー リミティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2008906650A external-priority patent/AU2008906650A0/en
Application filed by プラナ バイオテクノロジー リミティッド, プラナ バイオテクノロジー リミティッド filed Critical プラナ バイオテクノロジー リミティッド
Publication of JP2012513416A publication Critical patent/JP2012513416A/ja
Publication of JP2012513416A5 publication Critical patent/JP2012513416A5/ja
Application granted granted Critical
Publication of JP5719779B2 publication Critical patent/JP5719779B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2011542631A 2008-12-24 2009-12-23 キナゾリノン化合物 Expired - Fee Related JP5719779B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2008906650A AU2008906650A0 (en) 2008-12-24 Quinazolinone compounds
AU2008906650 2008-12-24
PCT/AU2009/001701 WO2010071944A1 (en) 2008-12-24 2009-12-23 Quinazolinone compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015058888A Division JP2015143249A (ja) 2008-12-24 2015-03-23 キナゾリノン化合物

Publications (3)

Publication Number Publication Date
JP2012513416A JP2012513416A (ja) 2012-06-14
JP2012513416A5 JP2012513416A5 (enExample) 2013-02-14
JP5719779B2 true JP5719779B2 (ja) 2015-05-20

Family

ID=42286805

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011542631A Expired - Fee Related JP5719779B2 (ja) 2008-12-24 2009-12-23 キナゾリノン化合物
JP2015058888A Pending JP2015143249A (ja) 2008-12-24 2015-03-23 キナゾリノン化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015058888A Pending JP2015143249A (ja) 2008-12-24 2015-03-23 キナゾリノン化合物

Country Status (6)

Country Link
US (3) US8889695B2 (enExample)
EP (1) EP2379510B1 (enExample)
JP (2) JP5719779B2 (enExample)
DK (1) DK2379510T3 (enExample)
ES (1) ES2634492T3 (enExample)
WO (1) WO2010071944A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015143249A (ja) * 2008-12-24 2015-08-06 プラナ バイオテクノロジー リミティッド キナゾリノン化合物

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667300B2 (en) * 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
ES2607804T3 (es) 2004-05-13 2017-04-04 Icos Corporation Quinazolinones como inhibidores de la fosfatidilinositol humana 3-quinasa delta
CN102271683B (zh) 2008-11-13 2014-07-09 吉里德卡利斯托加公司 恶性血液病的治疗
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
EP2421536B1 (en) * 2009-04-20 2015-08-26 Gilead Calistoga LLC Methods of treatment for solid tumors
US8691829B2 (en) 2009-07-21 2014-04-08 Gilead Calistoga Llc Treatment of liver disorders with PI3K inhibitors
WO2013134288A1 (en) 2012-03-05 2013-09-12 Gilead Calistoga Llc Polymorphic forms of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one
CA2886139A1 (en) 2012-12-27 2014-07-03 F. Hoffmann-La Roche Ag Comt inhibitors
CN105849108A (zh) 2013-12-20 2016-08-10 吉利德卡利斯托加公司 磷脂酰肌醇3-激酶抑制剂的制备方法
JP2017500319A (ja) 2013-12-20 2017-01-05 ギリアード カリストガ エルエルシー （ｓ）−２−（１−（９ｈ−プリン−６−イルアミノ）プロピル）−５−フルオロ−３−フェニルキナゾリン−４（３ｈ）−オンの塩酸塩の多形形態
MX2016016530A (es) 2014-06-13 2017-03-27 Gilead Sciences Inc Inhibidores de fosfatidilinositol 3-quinasa.
CN104016929B (zh) * 2014-06-25 2016-03-30 北京理工大学 一种合成喹唑啉-4(3h)-酮的方法
US10781178B2 (en) 2015-08-12 2020-09-22 The General Hospital Corporation 8-hydroxyquinoline derivatives as diagnostic and therapeutic agents
WO2025059726A1 (en) * 2023-09-22 2025-03-27 Alterity Therapeutics Limited Novel therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2361403T3 (es) * 2002-03-07 2011-06-16 X-Ceptor Therapeutics, Inc. Moduladores de quinazolinona de receptores nucleares.
EP1558585B1 (en) * 2002-10-04 2013-09-25 Prana Biotechnology Limited Neurologically-active compounds
ATE440825T1 (de) * 2003-06-06 2009-09-15 Vertex Pharma Pyrimidin-derivate zur verwendung als modulatoren von atp-bindende kassette transportern
MXPA06011236A (es) * 2004-04-02 2007-01-16 Prana Biotechnology Ltd Compuestos neurologicamente activos.
ES2437997T3 (es) * 2006-04-14 2014-01-15 Prana Biotechnology Limited Método de tratamiento de la degeneración macular relacionada con la edad (AMD)
JP5415942B2 (ja) * 2006-06-22 2014-02-12 プラナ バイオテクノロジー リミティッド 処置の方法およびその処置に有用な薬剤
WO2008074068A1 (en) * 2006-12-20 2008-06-26 Prana Biotechnology Limited Substituted quinoline derivatives as antiamyloidogeneic agents
ES2634492T3 (es) * 2008-12-24 2017-09-28 Prana Biotechnology Ltd Compuestos de quinazolinona

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015143249A (ja) * 2008-12-24 2015-08-06 プラナ バイオテクノロジー リミティッド キナゾリノン化合物

Also Published As

Publication number Publication date
US8889695B2 (en) 2014-11-18
AU2009329833A1 (en) 2011-07-14
US20150359796A1 (en) 2015-12-17
DK2379510T3 (en) 2016-12-19
AU2009329833A2 (en) 2011-07-14
US9145375B2 (en) 2015-09-29
EP2379510A4 (en) 2012-08-08
EP2379510A1 (en) 2011-10-26
ES2634492T3 (es) 2017-09-28
US20120040980A1 (en) 2012-02-16
JP2015143249A (ja) 2015-08-06
EP2379510B1 (en) 2016-10-26
JP2012513416A (ja) 2012-06-14
US20150025072A1 (en) 2015-01-22
WO2010071944A1 (en) 2010-07-01

Similar Documents

Publication Publication Date Title
JP5719779B2 (ja) キナゾリノン化合物
US11053207B2 (en) Indoleamine-2,3-dioxygenase inhibitor and preparation method therefor
JP6196986B2 (ja) 麻酔化合物および関連する使用方法
JP4685243B2 (ja) ピリミド［６，１−ａ］イソキノリン−４−オン誘導体
RU2559888C2 (ru) Аналоги этомидата, которые не ингибируют синтез адренокортикостероидов
EP3983384A1 (en) N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as gpr17 modulators for treating cns disorders such as multiple sclerosis
RU2624446C2 (ru) Трициклические соединения, композиции, содержащие указанные соединения, и их применения
FI67686B (fi) Foerfarande foer framstaellning av nya terapeutiskt anvaendbara fenetanolaminderivat
WO2019173761A1 (en) C-abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same
WO2009051909A1 (en) Compounds having activity in correcting mutant-cftr cellular processing and uses thereof
KR100298377B1 (ko) 엔엠디에이(NMDA)수용체길항물질인2,5-디옥소-2,5-디히드로1H-벤즈(b)아제핀
WO2023081892A1 (en) Analogs of n,n,n-trimethyl-4-phosphoryloxytryptamine
CN104519882A (zh) 治疗赛多孢子菌属感染的方法
CN110191885A (zh) 作为蛋白质聚集调节剂的烷氧基双-杂芳基衍生物
JP2013516458A (ja) ５−ｈｔ６受容体リガンドとしてのスルホン化合物
AU2009329833B2 (en) Quinazolinone compounds
KR101115196B1 (ko) 2-아미노벤조일 유도체
WO2015062555A1 (zh) 具有更高蛋白激酶g抑制活性的化合物及其制备方法
KR102511507B1 (ko) 신규한 벤조인다졸트리온 유도체 및 이의 용도
US20070004777A1 (en) Methods for treating or preventing acute myelogenous leukemia
EP2588109A1 (en) Use of kynurenic acid amide derivatives for the treatment of huntington's disease
CN119874686A (zh) 氘代苯并咪唑衍生物及其制备方法和用途
JP2018154562A (ja) 新規二環式複素環化合物およびその医薬用途
CN101018772B (zh) 神经活性化合物
CN117720580A (zh) 含氮芳基磷氧化物、其制备方法和应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140812

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150310

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150323

R150 Certificate of patent or registration of utility model

Ref document number: 5719779

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees